BioCentury | Jul 18, 2020
Finance

Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

...2016 by David Andrews and Arthur Howe with a license to the immunotherapy technology from Thomas Jefferson University...
BioCentury | Jul 14, 2020
Regulation

GSK maintains lead in BCMA race with FDA panel’s recommendation

...public hearing portion of the meeting were in favor of approval. Wills Eye Hospital and Thomas Jefferson University...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...conduct a Phase II trial addressing inflammation due to SARS-CoV-2 infection. Biohaven will collaborate with Thomas Jefferson University...
...Staff Writer Ketas, ibudilast (AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University Thomas Jefferson University MediciNova...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

...Preclinical Founded: 2016 by Simon Tomlinson, John Williams, Uli Rodeck University collaborators: City of Hope, Thomas Jefferson University...
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

...Gutenberg University Mainz, Massachusetts General Hospital;, National Research Council, Scripps Research Institute, Tel Aviv University, Thomas Jefferson University...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

...published online Nov. 6, 2018 doi:10.1016/j.celrep.2018.10.049 CONTACT: Andrew E. Aplin, Thomas Jefferson University, Philadelphia, Pa. email: andrew.aplin@jefferson.edu Claire Quang Thomas Jefferson University BRAF Melanoma...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...Yale University, New Haven, Conn. email: qin.yan@yale.edu CONTACT: Haifeng Yang, Thomas Jefferson University, Philadelphia, Pa. email: haifeng.yang@jefferson.edu Claire Quang Thomas Jefferson University Vanderbilt...
BioCentury | Sep 29, 2018
Product Development

Deferred differentiation in migraine

...we know they work, they work quickly, and they have minimal side effects.” Stephen Silberstein, Thomas Jefferson University...
...said Stephen Silberstein, director of the Jefferson Headache Center and a professor of neurology at Thomas Jefferson University...
...National Headache Foundation, Chicago, Ill. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petah Tikva, Israel Thomas Jefferson University...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

...are activated by tumor-associated proteases. The technology was exclusively licensed from City of Hope and Thomas Jefferson University...
BioCentury | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...reaching the tumor microenvironment. Akrevia licensed the technology from City of Hope (Duarte, Calif.) and Thomas Jefferson University...
Items per page:
1 - 10 of 105
BioCentury | Jul 18, 2020
Finance

Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

...2016 by David Andrews and Arthur Howe with a license to the immunotherapy technology from Thomas Jefferson University...
BioCentury | Jul 14, 2020
Regulation

GSK maintains lead in BCMA race with FDA panel’s recommendation

...public hearing portion of the meeting were in favor of approval. Wills Eye Hospital and Thomas Jefferson University...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...conduct a Phase II trial addressing inflammation due to SARS-CoV-2 infection. Biohaven will collaborate with Thomas Jefferson University...
...Staff Writer Ketas, ibudilast (AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University Thomas Jefferson University MediciNova...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

...Preclinical Founded: 2016 by Simon Tomlinson, John Williams, Uli Rodeck University collaborators: City of Hope, Thomas Jefferson University...
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

...Gutenberg University Mainz, Massachusetts General Hospital;, National Research Council, Scripps Research Institute, Tel Aviv University, Thomas Jefferson University...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

...published online Nov. 6, 2018 doi:10.1016/j.celrep.2018.10.049 CONTACT: Andrew E. Aplin, Thomas Jefferson University, Philadelphia, Pa. email: andrew.aplin@jefferson.edu Claire Quang Thomas Jefferson University BRAF Melanoma...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...Yale University, New Haven, Conn. email: qin.yan@yale.edu CONTACT: Haifeng Yang, Thomas Jefferson University, Philadelphia, Pa. email: haifeng.yang@jefferson.edu Claire Quang Thomas Jefferson University Vanderbilt...
BioCentury | Sep 29, 2018
Product Development

Deferred differentiation in migraine

...we know they work, they work quickly, and they have minimal side effects.” Stephen Silberstein, Thomas Jefferson University...
...said Stephen Silberstein, director of the Jefferson Headache Center and a professor of neurology at Thomas Jefferson University...
...National Headache Foundation, Chicago, Ill. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petah Tikva, Israel Thomas Jefferson University...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

...are activated by tumor-associated proteases. The technology was exclusively licensed from City of Hope and Thomas Jefferson University...
BioCentury | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

...reaching the tumor microenvironment. Akrevia licensed the technology from City of Hope (Duarte, Calif.) and Thomas Jefferson University...
Items per page:
1 - 10 of 105